1、肾癌信号通路及免疫治疗进展调控肿瘤血管生成的信号通路 VHL-HIF-VEGF PI3K-Akt-mTORVHL-HIF-VEGFCampbell-Walsh Urology 10th edSantoni M et al. Int J Cancer. (2014)Buczek M et al. Biochim Biophys Acta. (2014) PI3K-Akt-mTORAlbiges L et al. Oncologist. (2012)Dienstmann R et al. Mol Cancer Ther. (2014)How can we manage resistance Adj
2、usting dose combination therapy Switch to another targeted therapy Development of novel agents targetingHouk BE et al. Cancer Chemother Pharmacol. (2010) 肾癌的免疫治疗 IFN IL-2 VaccineSantoni M et al. Int J Cancer. (2014)Checkpoint inhibitorKyi C, et al. FEBS Lett. (2014)CTLA4PD-1T细胞表达时间抗原接触后48h抗原长期接触后产生配
3、体表达由抗原提呈细胞表达CD80 (B7.1)/CD80 (B7.2) 肿瘤或炎性组织表达PD-L1 (B7-H1) 抗原提成细胞表达PD-L2 (B7-DC) 小鼠相关基因敲除由于自身免疫反应导致迅速死亡由于自身免疫反应导致慢性死亡阻断后反应抗肿瘤T细胞特异性弱抗肿瘤T细胞特异性强CTLA-4与PD-1区别PD-1/PD-L1 blockade in RCCPD-1Thompson RH, et al. Clin Cancer Res. (2007) Thompson RH, et al. Clin Cancer Res. (2007) PD-L1Thompson RH, et al. Ca
4、ncer Res. (2006)Jilaveanu LB et al. J Cancer. (2014)primary end point : comparison of PFS to assess whether a dose-response relationship exists. Secondary end points : PFS, objective response rate (ORR), time to response, duration of response, overall survival (OS), and AE rate.Tripathi A, et al. BioDrugs. (2014)Philips GK, et al. Int Immunol. (2014)Cancer ImmunotherapyAscierto PA, et al. J Transl Med. (2014)谢谢 谢！谢！
